# Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/anlotinib-versus-sunitinib-as-first-line-treatment-for-metastatic-renal-cell/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Aiping Zhou,Yuxian Bai,Yan Song,Hong Luo,Xiu-Bao Ren,Xiuwen Wang,Benkang Shi,Cheng Fu,Ying Cheng,Jiyan Liu,Shukui Qin,Jun Li,Hanzhong Li,Xianzhong Bai,Dingwei Ye,Jinwan Wang,Jianhui Ma |
| Citations | 115 |
| DOI | 10.1634/theoncologist.2018-0839 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1634/theoncologist.2018-0839 |
| OpenAlex ID | https://openalex.org/W2923519145 |
| PMID | 30902918 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Yan Song](https://scholariq.org/researchers/yan-song/)

## Paper journal

- [The Oncologist](https://scholariq.org/journals/the-oncologist/)

## Paper primary topic

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Paper topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.